Summary
KEY TOPICS
- What is the current landscape of continuing medical education (CME) in North America and Europe?
- What structural forms are used to deploy CME, optimize budgets & best deliver content?
- How rapidly is E-CME advancing?
- What CME delivery channels are preferred?
- What are the current trends and future directions of CME?
KEY METRICS
- Geographic delivery of CME
- Structural management of CME
- CME investment budgets for North America
- CME investment budgets for Europe
- CME investment staffing for North America
- CME investment staffing for Europe
- Mix of planned versus spontaneous CME investment
- Functional responsibility for CME
- Mix of CME delivery in North America (company directed versus 3rd party, etc.)
- Mix of CME delivery in Europe
- Background and experience of CME employees
- Tenure of CME employees
- Mix of CME delivery modes for North America
- Mix of CME delivery modes for Europe
- Use of E-CME in North America & Europe
- Effectiveness ratings for CME delivery activities in North America
- Effectiveness ratings for CME delivery activities in Europe
METHODOLOGY
This research was based on benchmark survey data and executive interviews of 30 participants from 26 pharmaceutical, biotechnology and medical education companies.
INDUSTRIES PROFILED
Biotech, Pharmaceutical, Manufacturing, Health Care
COMPANIES PROFILED
Alcon Laboratories, Wyeth Pharmaceuticals, TAP, Talecris, Sepracor, Sanofi-Aventis, Roche, Pfizer, Ortho-Clinical Diagnostics, Novo Nordisk, Novartis Canada, Serono, Merck, Johnson & Johnson, Genentech, Eli Lilly and Company, Daiichi Pharmaceutical Co; Ltd., Celgene, Bristol-Myers Squibb, Boehringer-Ingelheim, Baxter Healthcare, AstraZeneca, Amylin
|